Our four technology platforms — TransE™, NasoPass™, EndoEase™, and KinderDose™ — are designed to address long-standing challenges in drug delivery within healthcare. Whether it’s injection discomfort, limited drug efficacy, or palatability challenges in pediatric formulations, our technologies overcome these barriers and to bring advanced treatments into comfortable, effective everyday medical use.
Conventional delivery by injection of large-molecule drugs faces multiple challenges :
Dermatological Treatment : For many skin diseases, such as psoriasis, systemic drugs often fail to achieve adequate concentration at the site of inflammation.
TransE™
TransE™ leverages AI to optimize the delivery of large-molecule therapeutics, ensuring high local drug concentrations at disease sites. This targeted approach is particularly valuable for dermatological conditions like psoriasis.
Beyond its efficacy, TransE™ offers thermal stability. This feature eliminates the cold chain requirement, drastically reducing transportation and storage costs and enabling access to vital medicines in locations where refrigeration is limited or unavailable.
Achieving effective mucosal immunity in the respiratory tract remains a major challenge for both vaccines and antibody-based therapies. Two critical issues limit their success:
Intranasal Vaccines: These often fail to induce sufficient secretory IgA, diminishing mucosal immunity and weakening early protection against airborne pathogens. Furthermore, poor antigen adhesion and low formulation stability lead to rapid degradation, making them reliant on cold chain storage.
Antibody Therapies: Although these play an increasingly important role in chronic respiratory conditions like chronic rhinosinusitis, their usual administration by systemic injection leads to average bloodstream concentrations while often failing to maintain sufficient concentration levels at the inflammation site.
NasoPass™
NasoPass™ is an advanced intranasal platform that uses AI-optimized peptides to enhance drug absorption and stability. Its proprietary formulation keeps antigens and antibodies stable and bioactive at room temperature, eliminating cold chain needs. Designed for versatility, NasoPass™ effectively delivers mucosal vaccines and offers needle-free, targeted, and long-acting delivery of monoclonal antibodies directly to inflamed tissues for the treatment of conditions like chronic rhinosinusitis.
The demanding, long-term regimen of frequent injections for chronic conditions creates a ripple effect of challenges :
For Patients: The relentless routine of daily or frequent self-injections is disruptive, creating a constant burden of planning, inconvenience, and loss of spontaneity.
For Caregivers & Families: The responsibility of managing complex injection schedules and assisting with administration adds significant emotional and logistical stress to family life.
EndoEase™
The EndoEase™ delivery platform is completely transforming traditional injection methods. It allows for the rapid absorption of hormone and peptide medications through the sublingual (under the tongue) mucosa. This not only makes administration far simpler than injections but also offers flexible dosage adjustments, ensuring a more comfortable and hassle-free treatment experience.
Over 90% of medications worldwide aren’t specifically designed for pediatric use. This forces healthcare professionals to adapt adult formulations for children’s use, which involves significant clinical and practical challenges:
Swallowing Difficulty: Standard dosage forms like large tablets and capsules often cause children to choke, gag, or vomit.
Inaccurate Dosing: A common but unreliable practice for children’s medication is crushing tablets. When these powders don’t fully dissolve (especially in liquids like water or syrup), the actual dose a child receives can be significantly different from what’s prescribed, leading to unpredictable treatment outcomes.
Poor Palatability: Bitter or other unpleasant tastes frequently cause children to refuse medication.
KinderDose™
KinderDose™ is a pediatric drug delivery platform that leverages advanced liposomal technology to solve common medication challenges. It fully encapsulates medication within multi-layered lipid vesicles, which prevents drug settling and significantly reduces the risk of inaccurate dosing and inconsistent treatment outcomes. Furthermore, it effectively masks unpleasant flavors, boosting a child’s willingness to take their medicine.
We use cookies and similar technologies to personalize content, serve and measure ads, and enhance your experience. Click “Accept” to consent to all cookies, or click “Reject” to decline non‑essential cookies. For details, see our Privacy Policy.
